Select Language
Flt-3
Flt-3 Overview
| English Name | Tyrosine-protein kinase receptor FLT3 | Approved Drugs | 14 |
| Drugs in Clinical Trials | 60 | Target Synonym | EC:2.7.10.1，CD135 Antigen，CD135，STK1，Growth Factor Receptor Tyrosine Kinase Type III，Fms-Related Tyrosine Kinase 3，Fetal Liver Kinase 2，Fetal Liver Kinase-2，EC 2.7.10.1，fms-Like Tyrosine Kinase 3，Receptor-type tyrosine-protein kinase FLT3，FLT3，FLT-3，FLK2，STK-1，FL cytokine receptor，Fms Related Tyrosine Kinase 3，Stem Cell Tyrosine Kinase 1，FLK-2，Fms Related Receptor Tyrosine Kinase 3，EC 2.7.10 |
| Highest Development Stage | Approved | ||
| English Name | Tyrosine-protein kinase receptor FLT3 |
| Target Synonym | EC:2.7.10.1，CD135 Antigen，CD135，STK1，Growth Factor Receptor Tyrosine Kinase Type III，Fms-Related Tyrosine Kinase 3，Fetal Liver Kinase 2，Fetal Liver Kinase-2，EC 2.7.10.1，fms-Like Tyrosine Kinase 3，Receptor-type tyrosine-protein kinase FLT3，FLT3，FLT-3，FLK2，STK-1，FL cytokine receptor，Fms Related Tyrosine Kinase 3，Stem Cell Tyrosine Kinase 1，FLK-2，Fms Related Receptor Tyrosine Kinase 3，EC 2.7.10 |
| Approved Drugs | 14 |
| Drugs in Clinical Trials | 60 |
| Highest Development Stage | Approved |
Flt-3 Product List
- Product Category
Protein (6)
- Product Status
Launched (6)
- Species
Human (4)Mouse (1)Cynomolgus (1)
- Tag
Fc Tag (2)His Tag (3)His Tag & Avi Tag (1)
- Conjugate
Unconjugated (4)Biotin-labeled (1)FITC Labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature | Order Now |
|---|---|---|---|---|---|---|---|
HOT FL3-H52H6 |  Human | HEK293 | Human Flt-3 / Flk-2 Protein, His Tag (MALS verified) |  |  |  |  Add to Cart |
HOT FL3-H82E3 | Human | HEK293 | Biotinylated Human Flt-3 / Flk-2 Protein, His,Avitag™ (MALS verified) |  | | | Add to Cart |
HOT FL3-C52H5 |  Cynomolgus | HEK293 | Cynomolgus Flt-3 / Flk-2 Protein, His Tag (MALS verified) | | | Add to Cart | |
FL3-H5258 | Human | HEK293 | Human Flt-3 / Flk-2 Protein, Fc Tag (MALS verified) |  | | | Add to Cart |
FL3-HF255 | Human | HEK293 | FITC-Labeled Human Flt-3 / Flk-2 Protein, Fc Tag |  | | | Add to Cart |
FL3-M52H6 |  Mouse | HEK293 | Mouse Flt-3 / Flk-2 Protein, His Tag |  | | | Add to Cart |
Total: 6
- 1
Flt-3 Background
Flt-3(Receptor-type tyrosine-protein kinase FLT3) is also known as FLK-2(Fetal liver kinase-2), STK-1(Stem cell tyrosine kinase 1), CD135. FLT3 is a cytokine receptor which belongs to the receptor tyrosine kinase class III. Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways.
Flt-3 Synonyms
Flt-3,Flk-2,STK-1,CD135,FLK2,FLT-3
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| XY-0206 | XY-0206 | Phase 3 Clinical | Nanjing University Of Chinese Medicine | Leukemia, Myeloid, Acute; Solid tumours | Details |
| Clifutinib Besylate | HEC-73543 | Phase 3 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Leukemia, Myeloid, Acute | Details |
| KC1036 | KC1036; KC-1036 | Phase 3 Clinical | Beijing Konruns Pharmaceutical Co Ltd | Adenocarcinoma; Digestive System Neoplasms; Esophageal Squamous Cell Carcinoma; Hematologic Neoplasms; Neoplasm Metastasis; Sarcoma, Ewing; Solid tumours; Thymus Neoplasms | Details |
| Ruserontinib | SKLB-1028 | Phase 3 Clinical | CSPC Pharmaceutical Group Ltd, Sichuan University | Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Solid tumours | Details |
| Lestaurtinib | SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 | Phase 3 Clinical | Kyowa Hakko Kirin Co Ltd | Bone Marrow Neoplasms; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Neuroblastoma; Polycythemia Vera; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Prostatic Neoplasms; Psoriasis; Thrombocythemia, Essential | Details |
| Crenolanib Besylate | CP-868596-26; IND-112201; CP-868596; ARO-002; ARO-002-26; CP-868; 596-26; CP-868; 596 | Phase 3 Clinical | Pfizer Inc | Gastrointestinal Stromal Tumors; Glioma; Leukemia, Myeloid, Acute | Details |
| Flonoltinib maleate | Phase 3 Clinical | Chengdu Zenitar Biomedical Technology Co Ltd | Alopecia Areata; Filariasis; Graft vs Host Disease; Lymphohistiocytosis, Hemophagocytic; Myeloproliferative Disorders; Neoplasms; Polycythemia Vera; Primary Myelofibrosis; Thrombocythemia, Essential | Details | |
| HYML-122 | HYML-122; CHMFL-FLT3-122 | Phase 2 Clinical | Hefei Academy Of Physical Sciences, Chinese Academy Of Sciences, Hefei Cosource Pharmaceuticals | Leukemia, Myeloid, Acute | Details |
| Ningetinib Tosylate | CT-053-PTSA; CT-053 | Phase 2 Clinical | Hec Pharm Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Intestinal Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| MRX-2843 | UNC-2371; UNC-2025; MRX-2843 | Phase 2 Clinical | University Of North Carolina At Chapel Hill | Carcinoma, Non-Small-Cell Lung; Leukemia; Leukemia, Myeloid, Acute; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplastic Processes; Pathologic Processes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Solid tumours | Details |
| Emavusertib | AU-4948; CA-4948 | Phase 2 Clinical | Aurigene | Anemia; Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Melanoma; Myelodysplastic Syndromes; Pancreatic Neoplasms; Stomach Neoplasms; Urologic Neoplasms | Details |
| Zotiraciclib | SB-1317; TG-02 | Phase 2 Clinical | Syncore Biotechnology Co Ltd | Astrocytoma; Brain Neoplasms; Carcinoma, Hepatocellular; Glioblastoma; Glioma; Gliosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasms | Details |
| Nefextinib hemifumarate | MAX-40279-001; Max-40279; MAX-40279-01; MAX-4; MAX-5; Max-6 | Phase 2 Clinical | MaxiNovel Pharmaceuticals Co Ltd | Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Idiopathic Pulmonary Fibrosis; Leukemia; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasm Metastasis; Solid tumours; Stomach Neoplasms | Details |
| Merestinib | 5OGS5K699E; LY-2801653 | Phase 2 Clinical | Eli Lilly And Company | Biliary Tract Neoplasms; Bone metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Gallbladder Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Microsatellite instability-high cancer; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Solid tumours | Details |
| CDX-301 (Amgen) | CDX-301 | Phase 2 Clinical | Amgen Inc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Hodgkin Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Melanoma; Metastatic breast cancer; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms, Castration-Resistant; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Uveal melanoma | Details |
| Narazaciclib | HX-301; ON-123300 | Phase 2 Clinical | Temple University | Breast Neoplasms; Endometrial Neoplasms; Glioblastoma; Glioma; Multiple Myeloma; Solid tumours | Details |
| Tuspetinib | HM-43239 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes | Details |
| Flysyn | 4G8-SDIEM | Phase 2 Clinical | Synimmune Gmbh | Leukemia, Myeloid, Acute | Details |
| GB-3226 | BRM-1420; GB-3226 | Phase 2 Clinical | Bridge Medicines Inc | Leukemia, Myeloid, Acute | Details |
| Inhaled Nintedanib – dry powder (Avalyn Pharma) | AP02; AP 02 DP; AP-02; AP02-DP | Phase 2 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Pulmonary Fibrosis; Respiratory Tract Diseases | Details |
| Sorafenib Tosylate/Comekibart | MG-D-1609 | Phase 2 Clinical | Metagone Biotech Inc | Solid tumours | Details |
| Anti-FLT3 CAR-T Cell Therapy (PersonGen Biomedicine) | TAA05 | Phase 2 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Leukemia, Myeloid, Acute | Details |
| Mobinitinib fumerate | EP-0042 | Phase 2 Clinical | Ellipses Pharma | Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes | Details |
| LNK-01002 | LNK01002; LNK-1000318 | Phase 2 Clinical | Lynk Pharmaceutical (Hangzhou) Co Ltd | Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; Polycythemia Vera; Primary Myelofibrosis; Thrombocythemia, Essential | Details |
| Hydroxychloroquine/Sorafenib | Phase 2 Clinical | Vg Life Sciences | Ovarian Neoplasms; Solid tumours | Details | |
| Dapolsertib hydrochloride | SEL24/MEN1703; SEL24; SEL-24-B489; SEL-24; SEL-24-1; MEN-1703 | Phase 2 Clinical | Ryvu Therapeutics Sa | Leukemia, Myeloid, Acute; Lymphoma, B-Cell | Details |
| FN-1501 | FN-1501; LT-171-861 | Phase 2 Clinical | China Pharmaceutical University | Carcinoma, Hepatocellular; Leukemia, Myeloid, Acute; Neoplasms; Solid tumours | Details |
| Mivavotinib | TAK-659; CB-659 | Phase 1 Clinical | Takeda Pharmaceutical Co Ltd | Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| Emirodatamab | AMG-427 | Phase 1 Clinical | Amgen Inc | Leukemia, Myeloid, Acute | Details |
| E-6201 | E-6201 | Phase 1 Clinical | Eisai Co Ltd | Brain metastases; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Melanoma; Myelodysplastic Syndromes; Plaque psoriasis; Psoriasis; Solid tumours | Details |
| HEMO-CAR-T therapy(Hemogenyx) | HG-CT-1 | Phase 1 Clinical | Hemogenyx Pharmaceuticals PLC | Leukemia, Myeloid, Acute | Details |
| SENTI-202 | SENTI-202 | Phase 1 Clinical | Senti Biosciences Inc | Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| ETH-155008 | ETH-155008 | Phase 1 Clinical | Yunnan Shengke Pharmaceutical Co Ltd | Leukemia; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
| CLN-049 | CLN-049 | Phase 1 Clinical | Eberhard-Karls Universitaet Tuebingen, German Cancer Research Center (Dkfz) | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| Nintedanib Esylate Inhalation Powder(Cspc) | Phase 1 Clinical | Cspc-Nbp Pharmaceutical Co Ltd | Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis | Details | |
| DPH-001 | DPH-001; DPH001 | Phase 1 Clinical | Disruptive Pharma AB | Details | |
| BDT-272 | BDT272; BDT-272 | Phase 1 Clinical | Biodol Therapeutics | Pain | Details |
| TLX-83 | TLX83; TLX-83 | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Yantai New Drug Creation Shandong Laboratory, Zhejiang University, Zhongshan Institute for Drug Discovery | Leukemia, Myeloid, Acute | Details |
| QBH-196 | QBH-196 | Phase 1 Clinical | Shenyang Pharmaceutical University | Solid tumours; Stomach Neoplasms | Details |
| VX-A901 | VX-A901 | Phase 1 Clinical | Veraxa Biotech GmbH | Leukemia, Myeloid, Acute | Details |
| CI-135 | HR014; CI-135 | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Hematologic Neoplasms; Leukemia, Myeloid, Acute | Details |
| MNKD-201 | MNKD-201; MKND-201 | Phase 1 Clinical | MannKind Corp | Idiopathic Pulmonary Fibrosis | Details |
| ETN-101 | ETN101; ETN-101; MBP-11901 | Phase 1 Clinical | Etnova Therapeutics Corp | Carcinoma, Hepatocellular; Liver Neoplasms | Details |
| Lomonitinib | Phase 1 Clinical | Eilean Therapeutics LLC | Details | ||
| KME-0584 | KME-0584 | Phase 1 Clinical | Cincinnati Children'S Hospital Medical Center, National Center For Advancing Translational Sciences | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| Lomonitinib | ZE46-0134; ZE-46-0134; ZE-460134 | Phase 1 Clinical | Eilean Therapeutics LLC | Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute | Details |
| ETH-155036 | ETH-155036; ETH155036 | Phase 1 Clinical | Shengke Pharmaceutical (Jiangsu) Co Ltd | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| HPB-092 | HPB-092 | Phase 1 Clinical | Polymed Biopharmaceuticals Inc | Leukemia, Myeloid, Acute | Details |
| FF-10101 | FF-10101; FF-10101-01; FF-10101 succinate | Phase 1 Clinical | Fujifilm Corp | Leukemia, Myeloid, Acute | Details |
| STI-8591 | STI8591; STI-8591 | Phase 1 Clinical | Zhejiang Acea Pharmaceutical Co Ltd | Leukemia, Myeloid, Acute | Details |
| CTS-2016 | CTS-2016 | Phase 1 Clinical | CytosinLab Therapeutics Co Ltd | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| PLM-102 | PLM-102; PLD-102 | Phase 1 Clinical | Pelemed Co Ltd | Leukemia, Myeloid, Acute | Details |
| BMF-500 | BMF-500 | Phase 1 Clinical | Biomea Fusion Inc | Leukemia, Myeloid, Acute | Details |
| RG-6392 | RG-6392 | Phase 1 Clinical | F.Hoffmann-La Roche Inc | Neoplasms | Details |
| T-1301 | T-1301; DBPR-216; BPR-1J481; BPR1J481 | Phase 1 Clinical | Taivex Therapeutics Corp | Lymphoma; Solid tumours | Details |
| TT-00973 | TT-00973 | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Solid tumours | Details |
| Lasmotinib | PHI-101-002; PHI-101; PHI-101-003 | Phase 1 Clinical | Pharos iBio Co Ltd | Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Ovarian Neoplasms; Peritoneal Neoplasms | Details |
| Denfivontinib Hydrochloride | SKI-G-801; G-801; G-749 Hydrochloride | Phase 1 Clinical | Genosco | Leukemia, Myeloid, Acute; Solid tumours | Details |
| Luxeptinib | CG026806; CG-806; CG’806; CG-026806 | Phase 1 Clinical | Crystalgenomics Inc | Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes | Details |
| Sorafenib tosylate (Bio-Synectics) | BS-104 | Clinical | Bio-Synectics Inc | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Quizartinib | AC-010220; ASP-2689; AC-220 | Approved | Ambit Biosciences Co | Vanflyta | Japan | Leukemia, Myeloid, Acute | Daiichi Sankyo Co Ltd | 2019-06-18 | Hepatic Insufficiency; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Solid tumours | Details |
| Brigatinib | AP-26113 | Approved | Ariad Pharmaceuticals Inc | Alunbrig, ALUNBRIG | United States | Carcinoma, Non-Small-Cell Lung | Takeda Pharmaceuticals USA Inc | 2017-04-28 | Brain metastases; Carcinoma; Carcinoma, Non-Small-Cell Lung; Ependymoma; Granuloma, Plasma Cell; Lung Neoplasms; Lymphoma, Large-Cell, Anaplastic; Meningioma; Myofibroma; Neoplasms; Neurilemmoma; Neurofibromatosis 2; Neuroma, Acoustic; Sarcoma, Kaposi; Solid tumours | Details |
| Nintedanib Esylate | BIBF-1120 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Ofev, Vargatef | United States | Idiopathic Pulmonary Fibrosis | Boehringer Ingelheim International Gmbh | 2014-10-15 | Adenocarcinoma, Clear Cell; Appendiceal Neoplasms; Asbestosis; Astrocytoma; Breast Neoplasms; Carcinoid Tumor; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Endometrial Stromal Tumors; Esophageal Neoplasms; Fallopian Tube Neoplasms; Genital Neoplasms, Female; Glioblastoma; Gliosarcoma; Hepatic Insufficiency; Idiopathic Pulmonary Fibrosis; Leukemia, Myeloid, Acute; Lung Diseases, Interstitial; Mesothelioma; Multiple Myeloma; Neoplasms; Oligodendroglioma; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Pulmonary Fibrosis; Radiation Pneumonitis; Rejection of lung transplantation; Sarcoma; Scleroderma, Systemic; Silicosis; Small Cell Lung Carcinoma; Solid tumours; systemic sclerosis-associated interstitial lung disease; Telangiectasia, Hereditary Hemorrhagic; Uterine Neoplasms | Details |
| Vorolanib | CM-082; X-82; EYP-1901; XV-615 | Approved | Tyrogenex Inc | 伏美纳, DURAVYU™ | Mainland China | Carcinoma, Renal Cell | Betta Pharmaceuticals Co Ltd | 2023-06-07 | Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Choroidal Neovascularization; Diabetic macular oedema; Diabetic Retinopathy; Eye Diseases; Gastroesophageal Junction Neoplasms; Kidney Neoplasms; Leukemia, Myeloid, Acute; Macular Degeneration; Melanoma; Neoplasms; Pancreatic Neoplasms; Retinal Degeneration; Retinal Diseases; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Wet Macular Degeneration | Details |
| Gilteritinib Fumarate | ASP-2215 hemifumarate; ASP-2215; 66D-92MGC8M (UNII code) | Approved | Astellas Pharma Inc | Xospata | Japan | Leukemia, Myeloid, Acute | Astellas Pharma Inc | 2018-09-21 | Carcinoma, Non-Small-Cell Lung; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Lung Neoplasms; Renal Insufficiency; Solid tumours | Details |
| Pacritinib Citrate | ONX-0803; SB-1518 | Approved | S*BIO Pte Ltd | VONJO, Epjevy, ENPAXIQ | United States | Primary Myelofibrosis | Sobi | 2022-02-28 | Bone Marrow Diseases; Carcinoma, Non-Small-Cell Lung; Castleman Disease; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Graft vs Host Disease; Hematologic Diseases; Hepatic Insufficiency; Hodgkin Disease; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Leukemia, Myelomonocytic, Juvenile; Lymphoma; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Myelodysplastic Syndromes; Myeloproliferative Disorders; Polycythemia Vera; Primary Myelofibrosis; Sarcoma, Kaposi; Thrombocythemia, Essential; Thrombocytopenia; VEXAS Syndome; Waldenstrom Macroglobulinemia | Details |
| Fedratinib | TG-101348; SAR-302503 | Approved | Sanofi | Inrebic | United States | Primary Myelofibrosis | Bristol-Myers Squibb Company | 2019-08-16 | Hematologic Neoplasms; Hepatic Insufficiency; Leukemia, Neutrophilic, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms; Polycythemia Vera; Primary Myelofibrosis; Renal Insufficiency; Splenomegaly; Thrombocythemia, Essential | Details |
| Ponatinib Hydrochloride | AP24534 hydrochloride; AP24534-HCL; AP24534 HCl; INCB-84344; AP-24534 | Approved | Ariad | 英可欣, Iclusig | United States | Leukemia, Myelogenous, Chronic; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Ariad Pharmaceuticals Inc | 2012-12-14 | Adenocarcinoma of Lung; Blast Crisis; Carcinoma, Non-Small-Cell Lung; Common Bile Duct Neoplasms; Gastrointestinal Stromal Tumors; Glioblastoma; Head and Neck Neoplasms; Hematologic Neoplasms; Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic-Phase; Leukemia, Myelomonocytic, Chronic; Lymphoma; Medullary thyroid cancer (MTC); Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Small Cell Lung Carcinoma; Solid tumours; Thyroid Neoplasms | Details |
| Sunitinib Malate | PNU-290940AD; PHA-290940AD; SCAI-003; SU-010398; SU-11248; GB-102; PHA-290940; PNU-290940; SU-011248-L-malate salt | Approved | Pfizer Inc | Sutent, 索坦 | United States | Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell | Cppi Cv | 2006-01-26 | Abdominal Neoplasms; Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Islet Cell; Adrenocortical Carcinoma; AIDS-Related Complex; Amyloidosis; Angioimmunoblastic T-cell Lymphoma; Astrocytoma; Barrett Esophagus; Brain metastases; Brain Neoplasms; Breast Neoplasms; Burkitt Lymphoma; Carcinoma; Carcinoma, Acinar Cell; Carcinoma, Adenoid Cystic; Carcinoma, Adenosquamous; Carcinoma, Embryonal; Carcinoma, Hepatocellular; Carcinoma, Islet Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Choriocarcinoma; Chronic eosinophilic leukemia (CEL); Cognition Disorders; Colorectal Neoplasms; Diabetic macular oedema; Endodermal Sinus Tumor; Endometrial Neoplasms; Ependymoma; Esophageal Neoplasms; Fallopian Tube Neoplasms; Fibromatosis, Aggressive; Fibrosarcoma; Gastrointestinal Stromal Tumors; Germinoma; Glioblastoma; Glioma; Gliosarcoma; Head and Neck Neoplasms; Hemangi | Details |
| Pexidartinib | PLX-3397 | Approved | Daiichi Sankyo Co Ltd | Turalio | United States | Giant Cell Tumor of Tendon Sheath | Daiichi Sankyo Inc | 2019-08-02 | Arthritis, Rheumatoid; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Giant Cell Tumor of Tendon Sheath; Giant Cell Tumors; Glioblastoma; Hodgkin Disease; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Melanoma; Metastatic breast cancer; Neoplasm Metastasis; Neoplasms; Neurofibroma, Plexiform; Neurofibrosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Sarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Synovitis, Pigmented Villonodular | Details |
| Cabozantinib S-malate | XL-184; BMS-907351; RO7047650; RO-7047650 | Approved | Exelixis Inc | Cometriq, Cabometyx | United States | Thyroid Neoplasms; Carcinoma, Neuroendocrine | Exelixis Inc | 2012-11-29 | Adenocarcinoma, Clear Cell; Adenocarcinoma, Follicular; Adenoma, Islet Cell; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Astrocytoma; Bile Duct Neoplasms; Bone metastases; Brain metastases; Brain Neoplasms; Breast Neoplasms; Carcinoma, Adenosquamous; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Glioblastoma; Glioma; Gliosarcoma; Hepatic Insufficiency; Hepatoblastoma; HIV Infections; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Myeloid, Acute; Lymphoma; Medullary thyroid cancer (MTC); Melanoma; Meningioma; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroendocrin | Details |
| Sorafenib Tosylate | NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 | Approved | Onyx Pharmaceuticals Inc | Nexavar, 多吉美 | United States | Carcinoma, Renal Cell | Bayer Healthcare Pharmaceuticals Inc | 2005-12-01 | Abdominal Neoplasms; Adenocarcinoma; Angioimmunoblastic T-cell Lymphoma; Astrocytoma; Bile Duct Neoplasms; Brain Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Burkitt Lymphoma; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Islet Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Carcinoma, Verrucous; Cholangiocarcinoma; Colonic Neoplasms; Esophageal Neoplasms; Facial Neoplasms; Fallopian Tube Neoplasms; Fibromatosis, Aggressive; Gallbladder Neoplasms; Gastrinoma; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Glioblastoma; Gliosarcoma; Glucagonoma; Head and Neck Neoplasms; Heart Arrest; Hemangiosarcoma; Hepatopulmonary Syndrome; Histiocytoma, Malignant Fibrous; Hypertension, Portal; Hypopharyngeal Neoplasms; Insulinoma; Kidney Diseases; Kidney Neoplasms; Laryngeal Diseases; Laryngeal Neoplasms; Leiomyosarcoma; Leukemia, Basophilic, Acute; Leukemia, Eosin | Details |
| Famitinib Malate | SHR-1020 | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾比特 | Mainland China | Uterine Cervical Neoplasms | Jiangsu Hengrui Medicine Co Ltd | 2025-05-27 | Adenocarcinoma; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Gastrointestinal Stromal Tumors; Genital Neoplasms, Female; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Metastatic breast cancer; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic neuroendocrine tumors (pNET); Small Cell Lung Carcinoma; Solid tumours; Thyroid Neoplasms; Triple Negative Breast Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms | Details |
| Midostaurin | PKC-412; PKC-412A; CGP-41231; CGP-41251 | Approved | Novartis Pharma Ag | Rydapt | United States | Hematologic Neoplasms; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Leukemia, Mast-Cell | Novartis Pharmaceuticals Corp | 2017-04-28 | Hematologic Neoplasms; Hepatic Insufficiency; Leukemia; Leukemia, Mast-Cell; Leukemia, Myeloid, Acute; Mastocytosis; Mastocytosis, Systemic; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland